Boehringer Ingelheim to Acquires NBE-Therapeutics ~ $1.5B
Shots:
- Boehringer Ingelheim to acquire all shares of NBE-Therapeutics for ~$1.434B which include contingent clinical and regulatory milestones. The transaction is expected to be closed in Q1’21
- The acquisition will add NBE-Therapeutics’ ROR1-directed ADCs including NBE-002 which is currently in P-I studies for TNBC and other solid tumors
- NBE-Therapeutics’ iADC platform will add exceptional tumor-targeting capabilities to Boehringer Ingelheim’s oncology portfolio. The deal comes one month after Merck’s $2.8B acquisition of VelosBio for its anti-ROR1 ADC
Ref: Boehringer Ingelheim | Image: Business Wire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com